2024 – The FDA grants a breakthrough therapy designation for MindMed’s formulation of LSD for that treatment of generalized anxiousness condition.Alterations in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the five-HT2A receptorScientists had been also keen on the subjective outcomes